ESR1 and breast cancer: Professor Michael Dixon from the University of Edinburgh, Scotland on behalf of colleagues presented their in-depth analysis of ER positive breast cancers during development of endocrine resistance and demonstrated ‘subtype shift’ from luminal B to A in progressor patients treated with neo-adjuvant AIs.